Sofina Ventures, a key early investor in Indian beauty and personal care firm Honasa Consumer, sold shares worth approximately ₹177.2 crore via a bulk deal, marking continued partial exits amid strong company performance and strategic diversification.
- Sofina sold a 1.28% stake in Honasa Consumer for ₹177.2 Cr at a premium
- Honasa recently acquired 58% of Fluence Pharma to expand into nutraceuticals
- Early investors across Indian startups are increasingly offloading shares as capital infusion picks up
What happened
Sofina Ventures, an early backer of Honasa Consumer, executed a bulk share sale valued at around ₹177.2 crore, disposing of 41.78 lakh shares at ₹424.07 each, which reflected a slight premium over the stock’s closing price. This represented approximately a 1.28% equity stake in the parent company of brands such as Mamaearth and The Derma Co.
This sale adds to Sofina’s phased exit strategy following its initial investment during Honasa’s $50 million fundraising in 2021 and subsequent partial stake reductions during the company's IPO in November 2023 and further block sales in June 2024.
Why it matters
The stake sale coincides with an important strategic phase for Honasa Consumer, which recently announced the acquisition of a majority stake in Fluence Pharma, signaling its push into the growing nutraceuticals and supplements sector. This move aligns with the company’s broader growth ambition to more than double its revenue to over ₹5,500 crore by fiscal 2031 while improving profitability margins.
The bulk deal by Sofina also reflects a wider trend among early investors in Indian startups, many of whom are monetizing stakes in listed tech and D2C companies. While secondary sales rise, primary capital investment in India's startup ecosystem continues to increase, highlighted by fresh funding rounds such as CRED’s $900 million raise.
What to watch next
Market observers will monitor Honasa’s integration of Fluence Pharma and its progress against the aggressive 'Honasa 3.0' roadmap targeting rapid scale and margin expansion. The company’s share performance, which has rallied over 40% year-to-date, will also be an indicator of investor confidence in its evolving business model.
Additionally, the trajectory of secondary share sales by major institutional investors in India’s tech ecosystem will be important to watch, as they balance portfolio exits with the growing appetite for fresh capital injections into promising startups amid improving market conditions.